SCHEMBL14845112

SCHEMBL14845112

CCn1cc(C(=O)O)c(=O)c2c(O)c(OCc3ccc(OC)cc3)ccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.56
RAB9A P51151 2/20 0.56
ALDH1A1 P00352 2/20 0.56
HPGD P15428 2/20 0.56
HSD17B10 Q99714 2/20 0.56
TSHR P16473 1/20 0.56
CHRM1 P11229 2/20 0.48
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 3/20 0.42
KMT2A Q03164 1/20 0.42
ATM Q13315 1/20 0.42
LMNA P02545 1/20 0.41
ALKBH1 Q13686 1/20 0.41
PDE10A Q9Y233 1/20 0.40
PIK3CD O00329 1/20 0.40
PIK3R1 P27986 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CG P48736 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14845096 0.89 LMNA (0.47) KDM4ERAB9AALDH1A1HPGDHSD17B10
SCHEMBL15992147 0.82 KDM4E (0.67) KDM4ERAB9AALDH1A1HPGDHSD17B10
SCHEMBL14845106 0.81 POLB (0.47) ALDH1A1POLBKMT2ALMNAPDE10A
SCHEMBL14854395 0.80 KDM4E (0.53) KDM4ERAB9AALDH1A1HPGDHSD17B10
SCHEMBL14842552 0.80 KDM4E (0.53) KDM4ERAB9AALDH1A1HPGDHSD17B10
SCHEMBL14842998 0.78 RAB9A (0.53) KDM4ERAB9AALDH1A1HPGDHSD17B10
SCHEMBL14845181 0.76 KDM4E (0.55) KDM4ERAB9AALDH1A1HPGDHSD17B10
SCHEMBL15999546 0.75 KDM4E (0.54) KDM4ERAB9AALDH1A1HPGDHSD17B10
SCHEMBL14842965 0.73 KDM4E (0.52) KDM4ERAB9AALDH1A1HPGDHSD17B10
SCHEMBL395397 0.73 KDM4E (1.00) KDM4ERAB9AALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2763539-B1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LTD (GB) 2017-02-08 EP disclosed
US-9340556-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2016-05-17 US disclosed
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-09-04 US disclosed
EP-2763539-A1 ANTIBACTERIAL COMPOUNDS Glaxo Group Limited (GB) 2014-08-13 EP disclosed
WO-2013052568-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS MRPL21, PEPD, ABCB11 KDM4E 3556/4885RAB9A 423/4885ALDH1A1 3841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.